SG11201805423TA - Indolinones compounds and their use in the treatment of fibrotic diseases - Google Patents
Indolinones compounds and their use in the treatment of fibrotic diseasesInfo
- Publication number
- SG11201805423TA SG11201805423TA SG11201805423TA SG11201805423TA SG11201805423TA SG 11201805423T A SG11201805423T A SG 11201805423TA SG 11201805423T A SG11201805423T A SG 11201805423TA SG 11201805423T A SG11201805423T A SG 11201805423TA SG 11201805423T A SG11201805423T A SG 11201805423TA
- Authority
- SG
- Singapore
- Prior art keywords
- nottingham
- international
- treatment
- compounds
- sygnature
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1101111 0 11101 HOE HO 11111 0 111 010 1101H Ell 011100111E HOED International Bureau 0.. .... .. (10) International Publication Number ...... ... (43) International Publication Date WO 2017/109513 Al 29 June 2017(29.06.2017) WIPO I PCT (51) International Patent Classification: ited, 50-100 Holmers Farm Way, High Wycombe Bucking- CO7D 403/12 (2006.01) A61K 31/497 (2006.01) hamshire HP12 4EG (GB). CO7D 413/12 (2006.01) A61P 11/00 (2006.01) (74) Agents: TEUTEN, Andrew et al.; Three Globeside, Field- C07D 209/34 (2006.01) C07C 205/57 (2006.01) A61K 31/404 (2006.01) house Lane, Marlow, Buckinghamshire SL7 1HZ (GB). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/GB2016/054069 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, 23 December 2016 (23.12.2016) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (25) Filing Language: English KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (26) Publication Language: English MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (30) Priority Data: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 15202764.5 24 December 2015 (24.12.2015) EP TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (71) Applicant: RESPIVERT LIMITED [GB/GB]; 50-100 ZA, ZM, ZW. Holmers Farm Way, High Wycombe Buckinghamshire (84) Designated States (unless otherwise indicated, for every HP12 4EG (GB). kind of regional protection available): ARIPO (BW, GH, (72) Inventors: WALTERS, lain; c/o Sygnature Discovery GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Ltd, Biocity Nottingham, Pennyfoot Street, Nottingham TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Nottinghamshire NG1 1GF (GB). BIRCH, Louise; c/o TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Sygnature Discovery Ltd, Biocity Nottingham, Pennyfoot DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Street, Nottingham Nottinghamshire NG1 1GF (GB). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, HILL-COUSINS, Joseph; c/o Sygnature Discovery Ltd, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Biocity Nottingham, Pennyfoot Street, Nottingham Not- GW, KM, ML, MR, NE, SN, TD, TG). tinghamshire NG1 1GF (GB). COLLINGWOOD, Steph- Published: — _ en, Paul; c/o RespiVert Limited, 50-100 Holmers Farm = with international search report (Art. 21(3)) Way, High Wycombe Buckinghamshire HP12 4EG (GB). — STEVENSON, Christopher, Scott; c/o RespiVert Lim- _ = = = = = Title: INDOLINONES COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES (54) = = Z, R3 (I) = O . 1-1 NH R 1 i M 11 4 11 kf) C:r © 11 IN 1-1 (57) : The present invention relates inter alia to a compound of formula (I) Wherein R I , R 2 , R 3 and Z are as defined in the 0 specification and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in \" treatment, for example in the treatment of fibrotic diseases or interstitial lung diseases, in particular idiopathic pulmonary fibrosis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15202764 | 2015-12-24 | ||
| PCT/GB2016/054069 WO2017109513A1 (en) | 2015-12-24 | 2016-12-23 | Indolinones compounds and their use in the treatment of fibrotic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805423TA true SG11201805423TA (en) | 2018-07-30 |
Family
ID=55068868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805423TA SG11201805423TA (en) | 2015-12-24 | 2016-12-23 | Indolinones compounds and their use in the treatment of fibrotic diseases |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11046672B2 (en) |
| EP (2) | EP3722291B1 (en) |
| JP (1) | JP7068172B2 (en) |
| KR (1) | KR20180128390A (en) |
| CN (1) | CN109302846B (en) |
| AU (1) | AU2016376011B2 (en) |
| BR (1) | BR112018013033A2 (en) |
| CA (1) | CA3009778A1 (en) |
| CL (1) | CL2018001742A1 (en) |
| CO (1) | CO2018007663A2 (en) |
| DK (1) | DK3722291T3 (en) |
| EA (1) | EA038796B1 (en) |
| ES (2) | ES2956820T3 (en) |
| FI (1) | FI3722291T3 (en) |
| HR (1) | HRP20230833T1 (en) |
| HU (1) | HUE062784T2 (en) |
| IL (1) | IL260221A (en) |
| LT (1) | LT3722291T (en) |
| MX (1) | MX2018007852A (en) |
| MY (1) | MY195904A (en) |
| PH (1) | PH12018501575A1 (en) |
| PL (1) | PL3722291T3 (en) |
| PT (1) | PT3722291T (en) |
| RS (1) | RS64703B1 (en) |
| SG (1) | SG11201805423TA (en) |
| SI (1) | SI3722291T1 (en) |
| WO (1) | WO2017109513A1 (en) |
| ZA (1) | ZA201804950B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018012949B1 (en) | 2015-12-24 | 2023-11-14 | The Regents Of The University Of California | CFTR REGULATORS AND METHODS OF USE THEREOF |
| EA038773B1 (en) | 2016-03-08 | 2021-10-18 | Респиверт Лимитед | Indole derivatives and their use as protein kinase inhibitors |
| JP2020531511A (en) | 2017-08-24 | 2020-11-05 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Pharmaceutical composition for the eyeball |
| CN109678810B (en) * | 2019-01-23 | 2022-10-28 | 南京工业大学 | 1,2-oxygen nitrogen heterocyclic butane compound and preparation method and application thereof |
| AU2020386913A1 (en) * | 2019-11-20 | 2022-06-02 | Angion Biomedica Corp. | Methods for treating inflammatory bowel disease |
| CN111789842B (en) * | 2020-08-07 | 2021-09-21 | 南开大学 | Application of nintedanib in preparation of medicine for treating inflammatory bowel disease |
| CN113200936B (en) * | 2021-05-19 | 2022-10-21 | 南京工业大学 | 10-methylphenoxazine derivative, zirconium metal organic framework material thereof and preparation method |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA75054C2 (en) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Substituted in position 6 indolinones, producing and use thereof as medicament |
| DE10117204A1 (en) | 2001-04-06 | 2002-10-10 | Boehringer Ingelheim Pharma | Indolinones substituted in the 6-position, their preparation and their use as medicaments |
| JP2004182726A (en) | 2002-11-22 | 2004-07-02 | Yamanouchi Pharmaceut Co Ltd | 2-oxoindoline derivative |
| PE20060777A1 (en) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES |
| US20060154939A1 (en) * | 2004-12-24 | 2006-07-13 | Boehringer Ingelheim International Gmbh | Medicaments for the Treatment or Prevention of Fibrotic Diseases |
| WO2007008895A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Kinase inhibitors |
| US8344018B2 (en) | 2008-07-14 | 2013-01-01 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| EA038773B1 (en) | 2016-03-08 | 2021-10-18 | Респиверт Лимитед | Indole derivatives and their use as protein kinase inhibitors |
-
2016
- 2016-12-23 US US16/066,043 patent/US11046672B2/en active Active
- 2016-12-23 WO PCT/GB2016/054069 patent/WO2017109513A1/en active Application Filing
- 2016-12-23 EP EP20162043.2A patent/EP3722291B1/en active Active
- 2016-12-23 BR BR112018013033A patent/BR112018013033A2/en not_active Application Discontinuation
- 2016-12-23 MX MX2018007852A patent/MX2018007852A/en unknown
- 2016-12-23 PT PT201620432T patent/PT3722291T/en unknown
- 2016-12-23 LT LTEP20162043.2T patent/LT3722291T/en unknown
- 2016-12-23 FI FIEP20162043.2T patent/FI3722291T3/en active
- 2016-12-23 MY MYPI2018001087A patent/MY195904A/en unknown
- 2016-12-23 PL PL20162043.2T patent/PL3722291T3/en unknown
- 2016-12-23 EP EP16820318.0A patent/EP3394048B1/en active Active
- 2016-12-23 EA EA201891506A patent/EA038796B1/en unknown
- 2016-12-23 SI SI201631745T patent/SI3722291T1/en unknown
- 2016-12-23 JP JP2018533630A patent/JP7068172B2/en active Active
- 2016-12-23 CN CN201680082097.2A patent/CN109302846B/en active Active
- 2016-12-23 ES ES20162043T patent/ES2956820T3/en active Active
- 2016-12-23 SG SG11201805423TA patent/SG11201805423TA/en unknown
- 2016-12-23 HR HRP20230833TT patent/HRP20230833T1/en unknown
- 2016-12-23 RS RS20230860A patent/RS64703B1/en unknown
- 2016-12-23 DK DK20162043.2T patent/DK3722291T3/en active
- 2016-12-23 KR KR1020187020374A patent/KR20180128390A/en unknown
- 2016-12-23 HU HUE20162043A patent/HUE062784T2/en unknown
- 2016-12-23 ES ES16820318T patent/ES2796358T3/en active Active
- 2016-12-23 CA CA3009778A patent/CA3009778A1/en not_active Abandoned
- 2016-12-23 AU AU2016376011A patent/AU2016376011B2/en active Active
-
2018
- 2018-06-24 IL IL260221A patent/IL260221A/en unknown
- 2018-06-25 CL CL2018001742A patent/CL2018001742A1/en unknown
- 2018-07-23 ZA ZA201804950A patent/ZA201804950B/en unknown
- 2018-07-24 CO CONC2018/0007663A patent/CO2018007663A2/en unknown
- 2018-07-24 PH PH12018501575A patent/PH12018501575A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805423TA (en) | Indolinones compounds and their use in the treatment of fibrotic diseases | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201804363UA (en) | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | |
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201806700RA (en) | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201806980TA (en) | Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201809470RA (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto |